Navigation Links
Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:3/25/2013

WASHINGTON, March 25, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company held a pre-NDA meeting with the Division of Neurology Products of the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for filing a New Drug Application (NDA) for tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24).  Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.  Currently there is no FDA approved treatment for Non-24.

At the pre-NDA meeting, the FDA confirmed that the efficacy and safety data proposed by Vanda to be submitted in the tasimelteon NDA for Non-24 is adequate to support filing.  The NDA supporting package that includes data from clinical pharmacology, pre-clinical pharmacology program, chemistry and manufacturing was also deemed adequate to support filing.

"We are pleased with the positive interaction we had with the FDA as we are moving closer to providing a treatment for blind individuals with Non-24," said Mihael H. Polymeropoulos , M.D., President and CEO of Vanda. 

Based on this successful completion of the pre-NDA meeting, Vanda is targeting an NDA submission for tasimelteon in mid-2013.

About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.   

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
2. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
3. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
4. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
5. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
6. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
7. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
8. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
9. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
10. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
11. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 Inovio Pharmaceuticals, Inc. ... a conference call to report its second quarter 2014 ... AM ET. CEO Dr. J. Joseph Kim ... quarter earnings, provide a corporate update, and participate in ... clinical development plans for VGX-3100, Inovio,s immune therapy targeting ...
(Date:8/1/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Tricalcium ... Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... Global and China Potassium Nitrate  Industry" is a ... China and Global Potassium Nitrate  market. ...
(Date:7/31/2014)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) ... Chief Business Officer and Executive Vice President. Mr. Singh died ... "Sorrento is deeply saddened and shocked by the ... go to Amar,s family and friends," said Henry Ji ... Mr. Singh joined Sorrento in January 2014 from Synta ...
Breaking Medicine Technology:Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... Society for Biomolecular Sciences Conference, THE WOODLANDS, ... Incorporated announced that data was presented,today highlighting ... Genentech, Inc. at the Society for Biomolecular,Sciences ... These target discoveries were made in a ...
... BASKING RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ ... company focused on acquiring, developing and,commercializing targeted ... of VQD- 002, a direct inhibitor of ... hematologic tumors.,Pre-clinical data was presented in a ...
Cached Medicine Technology:Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:8/1/2014)... August 01, 2014 The evolving ... independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and ... with practices and resources to enhance patient care ... focused on critical issues to give independent pharmacists ... grow. , ThoughtSpot show attendance experienced a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, medical ... boosting healthcare market growth, although a reduction in ... generic consumption is a major challenge. , Turkey’s ... having grown at a Compound Annual Growth Rate ... the Health Transformation Program (Saglikta Donus, um Programi, ...
(Date:8/1/2014)... (HealthDay News) -- Patients with the progressive, deadly respiratory ... a new weapon to battle the disease, the U.S. ... agency approved a new treatment, an inhaled spray called ... of Americans. COPD, which is often linked to smoking, ... emphysema. Patients with COPD may experience a ...
(Date:8/1/2014)... August 01, 2014 For years, proponents ... A recent study conducted by the Ohio ... too far behind in terms of their health and ... know what’s best for their baby. So does this ... Dr. Steven Shapiro , chair of Pediatrics at ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Oxford ... company develops biomarkers. Its products include CytoSure heamatological ... +SNP Array, CytoSure ISCA UPD array, CytoSure ISCA ... array. OGT offers services, such as targeted sequencing ... service, miRNA analysis, gene expression analysis, cytosure services ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... ... ... ... ...
... The U.S. ,race gap, in the commission of violent crime ... arrest rates for African Americans out-distancing those for whites concludes ... University and the University of Oregon. While the gap ... grew again in the ,80s with the advent of crack cocaine. ...
... ... of the New England ADHD Treatment Center are excited to announce a new five week ... ... and Dr. Jeffrey Speller of the New England ADHD Treatment Center are excited to ...
... ... “ADDY” Awards at the 2010 ADDY Awards Ceremony presented in Akron, ... program is the largest advertising competition in the world. With over ... arguably toughest advertising competition. The ADDY Awards represents the true spirit ...
... ... ... , ... , ...
... the rate of growth of the cancer tumour. The standard ... This is the conclusion of scientists at the University of ... The principal reason that patients die of cancer is the ... tumours known as metastases. These metastases are initially so small ...
Cached Medicine News:Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 2Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 3Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 4Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 5Health News:Violent crime 'race gap' narrows, but persists in US 2Health News:Violent crime 'race gap' narrows, but persists in US 3Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 2Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 3Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 2Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 3Health News:Special Session Highlights Late-Breaking Abstracts 2Health News:Special Session Highlights Late-Breaking Abstracts 3Health News:Special Session Highlights Late-Breaking Abstracts 4Health News:Special Session Highlights Late-Breaking Abstracts 5
... Ossur range of prefabricated foot and ankle ... - from ankle instability to foot malalignment. ... designs and energy-return technology., ,Age is ... ankle foot orthoses provide a measure of ...
... The Stabilizing Ankle support features ... which lock the calcaneus into ... eversion and inversion. The full-circumference ... and stability. Ideal for chronic ...
... Walker Pediatric Boot is the ... boot that offers superior comfort ... two sizes are offered thus ... will fit left or right, ...
... The Bledsoe PTB Boot is ... alternative to casting for the mid-tibia ... providing patella tendon bearing support. The ... designed for range of motion from ...
Medicine Products: